Literature DB >> 7667643

Mycobacterium marinum arthritis.

J A Alloway1, S M Evangelisti, J S Sartin.   

Abstract

Mycobacterium marinum is an atypical acid-fast organism that is rarely associated with septic arthritis. Most often this is seen in patients with monarticular synovitis of the hands or wrists, especially in association with a history of periarticular trauma or exposure to marine environments. From tissue obtained by aspiration or synovectomy, Mycobacterium marinum can be identified by Ziehl-Nielson stain and has optimal growth in Lowenstein-Jenson medium. Therapy should consist of at least two antimycobacterial agents for a minimum 6 months. Surgical debridement also may be beneficial. The clinician must have a high index of suspicion that exposure to Mycobacterium marinum has occurred so appropriate stains and cultures can be obtained and antimycobacterial therapy initiated.

Entities:  

Mesh:

Year:  1995        PMID: 7667643     DOI: 10.1016/s0049-0172(95)80007-7

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  5 in total

1.  Differential trafficking of live and dead Mycobacterium marinum organisms in macrophages.

Authors:  L P Barker; K M George; S Falkow; P L Small
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

2.  "You never asked doc., I do fish".

Authors:  Fawad Aslam; Bernard Ng
Journal:  Clin Rheumatol       Date:  2009-09-01       Impact factor: 2.980

3.  Osteomyelitis Infection of Mycobacterium marinum: A Case Report and Literature Review.

Authors:  Hao H Nguyen; Nada Fadul; Muhammad S Ashraf; Dawd S Siraj
Journal:  Case Rep Infect Dis       Date:  2015-01-18

4.  Clinical Implications for the Timely Diagnosis of Mycobacterium marinum in the Age of Biologic Therapy: A Case Report and Review of the Literature.

Authors:  Chris J Lata; Kelle Edgar; Stephen Vaughan
Journal:  Case Rep Infect Dis       Date:  2017-03-14

5.  Invasive Mycobacterium marinum infections.

Authors:  Timothy Lahey
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.